Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED
Abroad (travel likely)Recruiting
Conditions
Dry Eye Syndromes · Dry Eye Disease (DED)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
S.C. di Oculistica Azienda Ospedaliero-Universitaria di Cagliari Presidio San Giovanni di Dio, Cagliari, CA, Italy
Contact: Principal Investigator (Giuseppe Giannaccare)U.O. Oculistica Azienda Ospedaliero-Universitaria Renato Dulbecco, Catanzaro, CZ, Italy
Contact: Principal Investigator (Vincenzo Scorcia)